<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945163</url>
  </required_header>
  <id_info>
    <org_study_id>2016-M-2</org_study_id>
    <nct_id>NCT02945163</nct_id>
  </id_info>
  <brief_title>Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy</brief_title>
  <official_title>The Optimization of HAART for Chinese——a RCT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Nanjing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral
      therapy in developing countries. Based on our previous data, we aim to evaluate whether
      reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects
      while not scarifying their virological efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with HIV RNA&lt;50 Copies/ml</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir Disoproxil Fumarate</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV antibody positive

          -  Chinese nationality

          -  Naïve to antiretroviral therapy

          -  Willing to start antiretroviral therapy

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or lactating

          -  Females try to get pregnant during the research period

          -  Subjects who allergic to any of the research drugs

          -  Subjects that taking other drugs that known to impact the absorption, distribution,
             metabolism and excretion of the research drugs

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             Investigator, would interfere with treatment, assessment, compliance with the
             protocol, or subject safety. This would include any active clinically significant
             renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease)
             illness, or malignancy

          -  Medical or psychiatric condition or occupational responsibilities that may preclude
             compliance with the protocol

          -  Laboratory blood values:

          -  Haemoglobin &lt;9.0 grams/decilitre (g/dL)

          -  Neutrophil count &lt;1500/mm3

          -  Platelet count &lt;75,000/mm3

          -  Aspartate aminotransferase or Alanine transaminase &gt;3 times Upper Limit of Normal
             (ULN)

          -  Total bilirubin &gt;3 times Upper Limit of Normal (ULN)

          -  Subjects with an estimated creatinine clearance of &lt;90 mL/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiliang Hu</last_name>
      <phone>086-02585091722</phone>
      <email>huzhiliangseu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
      <email>qtchenjun@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Rong Chen</last_name>
      <phone>086-17349752507</phone>
      <email>fanchen8123@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Yunnan provincial infectious disease hosipital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronghui Xie, M.D</last_name>
      <phone>086-15288334026</phone>
      <email>ynxrh@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

